I think, Psychology expert and neurologist should also be there in this kind of study..

Hi Vijay

I like the concept behind it but sorry to say this is not testable to my knowledge.

I think this is a tough and maybe impossible kit to develop... it would mean that a body would need to produce a specific metabolite that would indicate this and most likely one associated to stress like Cortisol but such production would not indicate that the person was going to suicide as often the drivers are Psychological and one person with high levels will behave differently than another. 

Pregnancy, cancer etc are yes/no answers, suicide is not so defined if it was  a specific metabolite produced sadly this would have many implications that would not all be positive. 

Regards 

G

I think you have to estimate the chemical change occur during suicide based on that you may developed the sensor

You may find some inspiration in a study done two decades ago that looked at this from an epidemiological perspective: Eur Psychiatry. 1996;11(1):21-33. doi: 10.1016/0924-9338(96)80455-X.

Biochemical, metabolic and immune correlates of seasonal variation in violent suicide: a chronoepidemiologic study.

Maes M1, Scharpé S, D'Hondt P, Peeters D, Wauters A, Neels H, Verkerk R.

Author information

Abstract

The purpose of this chronoepidemiologic study was to investigate the time-relationships between the yearly variations in occurrence of violent suicide in Belgium and the yearly variations in various biochemical, metabolic and immune variables in the Belgian population. The weekly mean number of deaths due to violent suicide for all of Belgium for the period 1979-1987 was computed. Twenty-six normal volunteers had monthly blood samplings during one calendar year for assays of plasma L-tryptophan (L-TRP), competing amino acids (CAA), and melatonin levels, maximal [3H]paroxetine binding to platelets, serum total cholesterol, calcium, magnesium, and soluble interleukin-2 receptor concentrations, and number of CD4+ T, CD8+ T and CD20+ B lymphocytes. The annual rhythm in violent suicide rate is highly significantly synchronized with the annual rhythms in L-TRP, [3H]paroxetine binding, cholesterol, calcium, magnesium, CD20+ B cells, and CD4+/CD8+ ratio; the mean peak (violent suicide, [3H]paroxetine binding) or nadir (all other variables) occurs around 3 May. There were significant inverse time-relationships between the time series of violent suicide rate and L-TRP, L-TRP/CAA ratio, total cholesterol, calcium and magnesium, CD4+/CD8+ T cell ratio and number of CD20+ B cells. Maximal [3H]paroxetine binding to platelets was significantly and positively related to the time series of violent suicide. An important part (56.4%) of the variance in mean weekly number of violent suicide rate was explained by the time series of L-TRP, cholesterol and melatonin.

There has been a good deal of research into biomarkers of suicide risk, some of it very promising. The topic is discussed in depth in "The Neurobiological Basis of Suicide" (see link to text below). While such research is fascinating and may someday lead to a noninvasive or at least minimally invasive tool, it may only represent a validation of what a good psychiatric risk assessment can provide. Also as indicated in an earlier answer, the psychosocial risk factors critical to assessment ant treatment will not show up in a blood draw or swab.

Tony

http://www.ncbi.nlm.nih.gov/books/NBK107201/

No.

At the current time, no.  Practically all, if not all, studies and research on suicidality have taken a trans-nosological approach.  That is, they include all suicidal people into the same studies.  This would be akin to putting all people with cancer into the same studies and hoping to get clear results. 

In order to make progress in cancer research, and all other areas of research, clinicians needed to take a phenomenological approach by describing the phenomena experienced by the patients.  In the case of suicidality, there seems to be multiple phenotypes.  Last year I co-authored an eBook for researchers that contains a phenotypic suicidality disorders classification and criteria.  We also have a structured diagnostic interview (a version of the Mini International Neuropsychiatric Interview [MINI] for Suicidality Disorders Studies) to use to classify a patient's experiences into each phenotype.  (The listing on ResearchGate is attached.  One of the chapters is in the supplemental files of that ResearchGate listing.  The eBook is available from HarmResearch.org.)  All of this allows each phenotype of suicidality to be studied at a time. 

Comparing phenotypic information with genetic and other biomarkers will lead to further, more accurate phenotypic criteria.  With this information each phenotype can be further studied going forward.  Similar to studying one phenotype of cancer.  Eventually this will allow for a higher potential to test for a genetic vulnerability to each phenotype of suicidality disorder. 

Within particular suicidality disorder phenotypes, we may also find specific biomarker data that would allow for regular testing of patients with suicidality, similar to how a diabetic person tests their blood glucose, which might give them forewarning to upcoming suicidality.

One subject with the Impulse Attack Suicidality Disorder (IASD) phenotype found she experienced red recurring papules on her fingers 30 days before an Unexpected Suicidal Impulse Attack (USIA). Tracking the red recurring papules allowed her to predict the USIAs.  Prior to this she felt paralyzed as she feared them happening at any moment of her life.

A USIA is an unexpected, unprovoked, urgent need to make a suicide attempt, which the subject can not control.  It often occurs with pre-cognitive symptoms.  It's kind of like a sneeze in that it is unexpected, unprovoked, difficult to control while experiencing, and people that sneeze tend to not have sneezing ideations prior to a sneeze (people that experience USIA's tend not to have suicidal ideations immediately prior to the USIA).

I suspect that a test could be developed to test for whatever caused these red recurring papules and could be used as warning for this subject.  (Having said that, it is not needed.  We were able to find a treatment for her suicidality which brought daily suicidality, sometimes ranging as low as 10 and as high as 800+ minutes of suicidality a day, down to 0 and she has been completely symptom free for nearly 2 years as long as she stays with the medication and treatment regimen [also described in the eBook and recently presented at American Society of Clinical Psychopharmacology's annual conference].)

In other words, do I think it is possible to create such a test at the current time? No. 

Do I think it will be possible in the near future (5 - 20 years)? Yes.

Book Suicidality: A Roadmap for Assessment and Treatment

Dear Sir/Madam,

Thanks a lot for your valuable replies.

Thanks

Unfortunately, I think NO. NEVER ... A Depression kit maybe; but depression does not lead to suicide automatically ... but to measure the whole range of suicidal ideation and behaviour ... NEVER ... SORRY. Suicide and Depression are two different things ... although there may be some relationship.